Table 2.
Index hospitalization for COVID-19 among patients with and without PCS.
| Characteristics | General n = 246 (100%) | PCS n = 187 (76%) | Without PCS n = 59 (24%) | p bivariate |
|---|---|---|---|---|
| COVID-19 compatible chest CT | 235 (96) | 181 (97) | 54 (92) | 0.08 |
| Severe lung involvement in chest CT | 174 (71) | 140 (75) | 34 (58) | 0.01 |
| SatO2 (%), median (IQR) | 83 (75–87) | 82 (74–86) | 85 (82–88) | 0.002 |
| PaO2/FiO2 ratio | 164.75 (92.13–251) | 155.32 (92.44–251) | 177.81 (89.11–252.38) | 0.90 |
| Intensive care unit admission | 76 (31) | 62 (33) | 14 (24) | 0.17 |
| Invasive mechanical ventilation | 73 (30) | 59 (32) | 14 (24) | 0.25 |
| Steroids for COVID-19 | 239 (97) | 183 (98) | 56 (95) | 0.23 |
| Antiviral for COVID-19 | 45(18) | 29(15.5) | 16(27) | 0.04 |
| Empirical antibiotic | 48 (20) | 36 (19) | 12 (20) | 0.81 |
| Hospital length stay (days) median (IQR) | 10 (6–20) | 10 (6–21) | 9 (5–19) | 0.20 |
| C Reactive protein, (mg/dL), median (IQR) | 11.13 (6.01–18.8) | 11.91 (6.66–19.26) | 9.45 (5.07–17.21) | 0.26 |
| Leucocytes (x 103/μL), median (IQR) | 8350 (5900–12300) | 8600 (6100–12600) | 7800 (5300–10800) | 0.12 |
| Lymphopenia (<1.0 × 103/μL) | 176 (71.5) | 131 (70) | 45 (76) | 0.35 |
| D dimer (ng/mL), median (IQR) | 699 (446–1191) | 704.5 (438–1168) | 682 (523–1245) | 0.33 |
| Ferritin (ng/mL), median (IQR) | 566.05 (260.95–1060.1) | 592.75 (280.8–1088) | 519.8 (192–879) | 0.15 |
| CPK (U/L), median (IQR) | 84 (43.5–161) | 79 (37–159) | 101 (54–190) | 0.11 |
| Lactic dehydrogenase (U/L), median (IQR) | 329 (262–437) | 327 (262–438) | 333.5 (265–420.5) | 0.97 |
| Fibrinogen (mg/dL), median (IQR) | 614 (462–767) | 635 (479–776) | 490.5 (429–710) | 0.006 |
PCS, post-COVID-19 syndrome; CT, computed tomography; IQR, interquartile range; SatO2, oxygen saturation; PaO2, partial pressure of arterial oxygen; FiO2, fraction of inspired oxygen; CPK, creatine phosphokinase. Bold values are values <0.05, which means that they are statistically significant.